Regular article
Treatment of high risk or recurrent meningiomas with hydroxyurea

https://doi.org/10.1054/jocn.2001.1019Get rights and content

Abstract

Recurrent, irresectable meningioma constitutes an uncommon but significant problem. Many systemic therapies have been tested without clear evidence of efficacy. More recently, two reports have suggested that hydroxyurea has activity in this context. This study examined the efficacy and toxicity of hydroxyurea in the treatment of 15 patients with high risk meningioma, residual meningioma post resection and progressive meningioma. Hydroxyurea was well tolerated although two patients ceased therapy because of skin rashes. There were no objective responses. Eleven patients achieved stable disease including eight patients who had documented progression prior to commencing hydroxyurea. These results are consistent with previous reports. In conclusion, hydroxyurea may provide some clinical benefit in patients with progressive meningioma by delaying progression of disease.

References (13)

  • MF Milosevic et al.

    Radiotherapy for atypical or malignant intracranial meningioma

    Int J Radiat Oncol Biol Phys

    (1996)
  • MC Chamberlain

    Meningiomas

    Curr Treat Options Neurol

    (2001)
  • F DeMonte et al.

    Meningiomas

  • MF Gonzales

    Classification of brain tumors

  • BJ Goldsmith et al.

    Post-operative irradiation for subtotally resected meningiomas

    A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg

    (1994)
  • SE Kaba et al.

    The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B

    Neurosurgery

    (1997)
There are more references available in the full text version of this article.

Cited by (66)

  • Medical Management of Meningiomas

    2023, Neurosurgery Clinics of North America

  • Benign Intracranial Tumors

    2018, Neurologic Clinics
    Citation Excerpt :

    However, treatment with the oral progesterone agonist megestrol acetate (Megace),42 the progesterone antagonist mifepristone (RU-486),43 and the estrogen receptor antagonist tamoxifen44 did not improve clinical outcomes. Other attempts using more traditional chemotherapies such as temozolomide,45 irinotecan,46 and hydroxyurea47–49 similarly did not definitively extend patient survival. Trials using biologically targeted approaches with imatinib (inhibitor of platelet-derived growth factor receptor [PDGFR] and c-KIT),50 erlotinib (inhibitor of epithelial growth factor receptor [EGFR]),51 and gefitinib (inhibitor of EGFR)51 also failed to show clinical benefit.

  • Role of hydroxyurea as an adjuvant treatment after Gamma knife radiosurgery for atypical (WHO grade II) meningiomas

    2018, Journal of the Egyptian National Cancer Institute
    Citation Excerpt :

    The 1, 3, and 5-year local tumor control was 91.1%, 59.3%, and 39.5%, respectively, for WHO grade II. The management of atypical meningiomas with chemotherapy has not been a standard of care even after many phase 2 trials have been published over the past 20 years [8–10], and [12]. One retrospective study suggested that adjuvant treatment after incomplete resection of atypical meningiomas is associated with longer PFS than conservative treatment.

  • Medical Management of Meningiomas. Current Status, Failed Treatments, and Promising Horizons.

    2016, Neurosurgery Clinics of North America
    Citation Excerpt :

    It was initially developed as a ribonucleotide reductase inhibitor inhibiting cell cycle for the treatment of myeloproliferative diseases and chronic myelogenous leukemia.4 In meningioma, hydroxyurea has shown a range in median PFS of 10 to 80 weeks and PFS-6 of 3% to 10%.52–61 These studies are limited by their retrospective design and small sample sizes.

  • Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies

    2016, World Neurosurgery
    Citation Excerpt :

    To date, the chemotherapy drug HU remains the most studied agent, but its efficacy has been modest at best.25-28 Since the publication of the initial study by Schrell et al.,25 subsequent study results have varied widely on their reported radiographic response, percentage of disease stabilization, and progression-free survival (PFS).15,25,29-34 Of note, these studies differ in their inclusion criteria with respect to denoting progression before HU treatment as well as monitoring previous or concurrent radiotherapy, which complicates study generalizability.

  • In vitro testing to a panel of potential chemotherapeutics and current concepts of chemotherapy in benign meningiomas

    2015, Surgical Oncology
    Citation Excerpt :

    Introduction of HU into the treatment of meningiomas was guided by the observations that the oral ribonucleotide inhibitor (a) reduces cellular proliferation by arresting the cell cycle in the S phase; (b) induces apoptosis in cultured human meningioma cells as well as in a nude mice model [27]; and (c) owing to acceptable and reversible side effects may be considered an ideal agent for treatment of a slowly growing tumours in which prolonged exposure to a chemotherapeutic drug is desirable [28]. Several small clinical trials showed disease stability [29,30] or even significant anti-tumour activity [31] following HU treatment. However, more recent [8] and larger [6] studies have not shown effectiveness in the treatment of non-resectable slow growing meningiomas: neither for achieving response, nor for arresting disease progression.

View all citing articles on Scopus
f1

Correspondence to: Mark A Rosenthal, Department of Medical Oncology and Clinical Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia 3050. Tel: +61-3-9342 7560; Fax: +61-3-9347 7508; E-mail:[email protected]

View full text
Copyright © 2002 Elsevier Science Ltd. All rights reserved.